MUC1 drives tumor progression in multiple tumor types (Kufe, 2009; de Paula Peres et al., 2015; Wurz et al., 2014) through activating important oncogenic proteins including EGFR, β‐catenin, NF‐κB, PKM2, and other pathways (Kufe, 2009; Singh and Hollingsworth, 2006; Wong et al., 2015). This evidence concerns the gene EGFR and neoplasm.